BIOHEART-B(02185): IBERIS RDN System registered in Indonesia.

BIOHEART-B (02185) announced that recently, its subsidiary Shanghai Antong Medical Technology Co., Ltd. (Antong) has registered the Iberis Multipolar Renal Artery Radiofrequency Ablation Catheter System (Iberis RDN System) in Indonesia. The registration is supported by Bosin International Group Limited (Bosin) and Antong. Antong and Bosin have formed a strategic partnership for the commercialization of the Iberis RDN System, with cooperation covering multiple regions including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of the date of this announcement, the Iberis RDN System is the only product globally approved for renal nerve denervation (RDN) using the Transradial Approach (TRA) and Transfemoral Approach (TFA). TRA makes RDN safer, more effective, and more cost-effective. The ultimate goal of the group is to provide outpatient RDN procedures for global patients. Antong obtained the CE mark for the Iberis RDN System in Europe in 2016.